Observational Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Aug 16, 2023; 11(23): 5468-5478
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5468
Table 1 Details of the genome-wide association studies included in this Mendelian randomization analysis
Exposures/Outcomes
Consortium
Ethnicity
Participants
Number of SNPs
Vitamin DUnited Kingdom BiobankEuropean4969466896093
Vitamin KCHAGREEuropean2138/
Vitamin EATBC&PLCO&NHSEuropean7781/
Vitamin AATBC&PLCO&NHSEuropean7778/
Vitamin B12SIIDEuropean45576/
Polycystic ovarian syndromeFinnGen BiobankEuropean11887016379676
HyperlipidaemiaFinnGen BiobankEuropean20149716380389
ObesityFinnGen BiobankEuropean21873516380465
Insulin resistanceMAGICEuropean370372435028
Table 2 Heterogeneity and pleiotropy tests of the Mendelian randomization analysis
Exposure/OutcomeHeterogeneity
Pleiotropy
Cochran’s Q
P value
Egger-intercept
P value
Vitamin D/PCOS180.6920.368 -0.006 0.487
Vitamin D/Hyperlipidaemia449.648< 0.001-0.004 0.425
Vitamin D/Obesity402.633< 0.0010.002 0.494
Vitamin D/Insulin resistance169.3120.001 -0.002 0.059
Vitamin K/PCOS2.9260.570 0.029 0.752
Vitamin K/Hyperlipidaemia5.1510.272 0.044 0.290
Vitamin K/Obesity7.0860.131 0.049 0.150
Vitamin K/Insulin resistance7.9320.094 -0.008 0.469
Vitamin B12/PCOS1.2840.973 0.004 0.930
Vitamin B12/Hyperlipidaemia3.3460.764 -0.022 0.297
Vitamin B12/Obesity5.0460.540 0.003 0.858
Vitamin B12/Insulin resistance3.5780.466 -0.003 0.451
Table 3 Mendelian randomization PRESSO estimates for effect of vitamin supplements on risk of polycystic ovary syndrome and its risk factors
Exposure trait
Outcome trait
N
Beta
P value
Vitamin DPCOS172-0.0920.645
Vitamin DHyperlipidaemia169-0.1410.126
Vitamin DObesity174-0.0310.618
Vitamin DInsulin resistance117-0.0050.789
Vitamin B12PCOS6-0.2840.005
Vitamin B12Hyperlipidaemia6-0.1030.063
Vitamin B12Obesity6-0.0880.048
Vitamin B12Insulin resistance6-0.0150.319